Clinical Trials Logo

Chronic Plaque-type Psoriasis clinical trials

View clinical trials related to Chronic Plaque-type Psoriasis.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04207801 Completed - Clinical trials for Chronic Plaque-type Psoriasis

A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis

INDUS-2
Start date: January 21, 2020
Phase: Phase 2
Study type: Interventional

This will be a multicenter, double-blind, double-dummy, placebo controlled, randomized study to evaluate efficacy and safety of AUR101 (RORgamma inhibitor) in patients with moderate-to-severe psoriasis. Approximately 90 patients with chronic moderate-to-severe plaque psoriasis will be randomized to the 2 dose groups of AUR101 and one group of Placebo. The patients will receive the treatment for 12 weeks.

NCT ID: NCT03553823 Completed - Clinical trials for Chronic Plaque-type Psoriasis

Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab

ARROW
Start date: January 14, 2019
Phase: Phase 2
Study type: Interventional

The aim of this study was to describe the effect of direct IL-17A inhibition with secukinumab as compared with the selective inhibition of IL-23 with guselkumab (p19 subunit blocker) in controlling inflammation in psoriatic plaques that remain active despite treatment with the non-selective IL-23 inhibitor ustekinumab (blocker of p40 subunit, shared by IL-12 and IL 23).

NCT ID: NCT02074982 Completed - Clinical trials for Chronic Plaque Type Psoriasis

Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis

Start date: February 25, 2014
Phase: Phase 3
Study type: Interventional

This study will assess efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis

NCT ID: NCT01828086 Completed - Clinical trials for Chronic Plaque-type Psoriasis

Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis

Start date: June 2013
Phase: Phase 1
Study type: Interventional

A randomized, double-blind, placebo and positive controlled, single and multiple dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CJM112 in chronic plaque-type psoriasis patients. This trial never made it to the Phase II part of this trial.

NCT ID: NCT01071252 Completed - Clinical trials for Chronic Plaque-type Psoriasis

A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Start date: March 2010
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body area is affected by the disease (compared to placebo).

NCT ID: NCT00941031 Completed - Clinical trials for Chronic Plaque-type Psoriasis

AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis

Start date: July 2009
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body area is affected by the disease (compared to placebo).